Sarah Cannon Research Institute (SCRI)

Denver, Colorado 80218

3 studies enrolling now · 3 studies all time

What they study most

Biliary Tract Cancer (BTC), Clear Cell Renal Cell Carcinoma (ccRCC), Gastric or Gastroesophageal Junction Adenocarcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Ductal Adenocarcinoma, Solid Tumors

Studies at this site

• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors — Recruiting now
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) — Recruiting now
• QTX3034 in Patients With KRAS G12D Mutation — Recruiting now